The 2027 Annual Update draft measure specifications are now available. Question and comment on Eligible Clinician eCQMs, Hospital - Inpatient eCQMs, and Hospital - Outpatient eCQM until December 19, 2025.
Top
Official websites use
.gov
A .gov website belongs to an official government organization in the United States.
Secure
.gov
websites use HTTPS
A
lock
(
)
or
https://
means you’ve safely connected to the
.gov
website. Share sensitive information only on official, secure websites.
["Type": "Adverse Reaction To Thrombolytics"]
Performance/Reporting Period
2023
Value Set Description from VSAC
Clinical Focus: The purpose of this value set is to represent concepts for adverse reactions to thrombolytic medications used for treatment of ST-segment elevation myocardial infaction (STEMI).
Data Element Scope: This value set may use a model element related to Disorder.
Inclusion Criteria: Includes SNOMED-CT codes that represent adverse reactions to thrombolytic medications for STEMI treatment.
Exclusion Criteria: No exclusions.
Data Element Scope: This value set may use a model element related to Disorder.
Inclusion Criteria: Includes SNOMED-CT codes that represent adverse reactions to thrombolytic medications for STEMI treatment.
Exclusion Criteria: No exclusions.
Constrained to codes in the Type: Adverse Reaction To Thrombolytics value set (2.16.840.1.113762.1.4.1170.6)
QDM Datatype and Definition
type
The characterization of the reaction (e.g., hypersensitivity, rash, gastroenteric symptoms, etc.).